Indication

Focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome

Focal segmental glomerulosclerosis without nephrotic syndrome describes a clinicopathologic presentation of glomerular disease characterized by histopathological scarring affecting portions of some, but not all, renal glomeruli. Read more about Focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome

1 drugs 1 manufacturers

Advertisement

Drugs that treat it

Common Focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome therapies.

Showing 1–1 of 1 drugs

FILSPARI (sparsentan)

ANGIOTENSIN II RECEPTOR ANTAGONISTS (ARBS)·IMMUNOGLOBULIN A NEPHROPATHY·+1
RETROPHIN, INC.
Filter & compare in the drug finder →Opens the drug finder with Focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome.

Focal segmental glomerulosclerosis without nephrotic syndrome describes a clinicopathologic presentation of glomerular disease characterized by histopathological scarring affecting portions of some, but not all, renal glomeruli.

Unlike classic primary presentations, affected pediatric and adult patients do not exhibit the complete nephrotic tetrad, manifesting instead with subnephrotic or asymptomatic proteinuria without severe hypoalbuminemia or generalized edema.

Pathophysiologically, this presentation typically reflects podocyte injury or detachment driven by secondary etiologies—such as hemodynamic maladaptation, hyperfiltration from reduced nephron mass, obesity, viral infections, or genetic podocytopathies—rather than circulating permeability factors.

Clinically, these individuals often present with progressive renal insufficiency or hypertension and generally require diagnostic differentiation from primary forms because their underlying mechanisms warrant distinct therapeutic approaches.

Personalize your experience

Follow Focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it